Point-of-care (POC) molecular diagnostics is rapidly evolving, driven by the need for faster, more accurate testing outside of traditional laboratories. The most innovative life sciences companies are at the forefront of this transformation, developing groundbreaking technologies that empower clinicians with real-time, actionable data. These platforms are decentralizing diagnostics and improving patient outcomes across various healthcare settings. Discover some of the key players in 2026.
1. Danaher
Danaher leads the field as one of the most innovative life sciences companies operating in POC molecular diagnostics. Its innovation centers on developing automated molecular systems and tests that are both accurate and easy to use. For example, the GeneXpert® System delivers rapid, reference-lab-quality results in a variety of settings, from hospitals to remote clinics.
By automating complex and time-consuming manual procedures, Danaher’s solutions enable sophisticated genetic testing for infectious diseases and oncology at the point of care. The company’s focus on decentralized, rapid, and actionable test results is a key aspect of its contribution to the field.
2. Abbott
Abbott’s key innovation in POC molecular diagnostics is its ID NOW™ platform. The system utilizes isothermal nucleic acid amplification technology to provide rapid molecular results, with the ID NOW COVID-19 test delivering results in 12 minutes or less.
The platform’s portability and ease of use have made it a widely adopted tool in a variety of near-patient settings. By providing fast, reliable molecular testing for infectious diseases like COVID-19, Influenza A and B, and Strep A, Abbott enables healthcare providers to make timely and informed treatment decisions.
3. Roche
Roche contributes to POC molecular diagnostics with its cobas® liat system. This compact and user-friendly system brings the accuracy of gold-standard technology directly to near-patient settings. It automates the entire testing process, from sample preparation to result interpretation, delivering results in 20 minutes or less.
The system offers a growing menu of single and multiplex assays for a variety of infectious diseases, including COVID-19, Influenza A and B, RSV, and Strep A. This enables rapid and accurate diagnosis, facilitating timely treatment decisions and improving patient management at the point of care.
4. bioMérieux
bioMérieux demonstrates its commitment to POC diagnostics with the BIOFIRE® SPOTFIRE® System. This brings multiplex technology to the near-patient setting, allowing for rapid and accurate diagnosis of infectious diseases during a single patient visit.
The SPOTFIRE system is designed for ease of use, with a small footprint and a streamlined workflow that requires minimal hands-on time. Its CLIA-waived multiplex panels can detect a broad range of viral and bacterial targets from a single sample in about 15-20 minutes.
Overview of life science companies and their technologies
Each of these companies is advancing the shift toward molecular diagnostics in different ways. Consider the following chart for an at-a-glance comparison.
| Company | Platform/System | Key features | Target applications |
|---|---|---|---|
| Danaher | GeneXpert | Automated, cartridge-based system with a broad menu of tests | Infectious diseases, oncology, genetics |
| Abbott | ID NOW | Portable, lightweight, easy to use | Infectious diseases |
| Roche | Cobas liat | Compact, automated, growing library of tests | Infectious diseases |
| bioMérieux | BIOFIRE SPOTFIRE | Small footprint, scalable, CLIA-waived multiplex panels | Respiratory and sexually transmitted infections |
Understanding POC molecular diagnostics
For a clinical laboratory professional, POC molecular diagnostics represents a significant evolution from traditional testing. While traditional POC tests are typically immunoassays or simple chemistry tests, molecular diagnostics brings the power of nucleic acid amplification directly to your patient’s bedside or a near-patient setting.
At its core, it’s about detecting the DNA or RNA of a pathogen or a specific biomarker in a patient sample, with a rapid turnaround time and no need for centralized laboratory testing. PCR is the gold standard for nucleic acid amplification, and this is now available in a compact, easy-to-use format.
Top life sciences companies demonstrate innovation with PCR systems designed to be “sample-to-answer,” meaning you simply add the patient sample to a cartridge and load it into the instrument. The system automates the rest of the process, from nucleic acid extraction and purification to amplification and detection.
The operational shift to POC diagnostics
The demand for faster, more actionable results is driving the adoption of POC molecular diagnostics. For a clinical lab, this represents a shift from a centralized testing model to a more decentralized one.
The main benefits include:
- Rapid turnaround time: POC molecular tests can provide results in as little as 15-20 minutes, compared to hours or even days for traditional lab-based molecular tests. This is critical in settings such as emergency departments, urgent care clinics, and physicians’ offices.
- Improved patient outcomes: Faster diagnosis leads to faster treatment. For example, a rapid diagnosis of influenza can enable the timely administration of antiviral medication, reducing the severity and duration of the illness.
- Enhanced antimicrobial stewardship: By rapidly identifying the specific pathogen causing an infection, clinicians can avoid the unnecessary use of broad-spectrum antibiotics
- Increased efficiency and workflow optimization: POC molecular testing can help to offload the burden of high-volume, routine tests. This frees up skilled laboratory personnel and resources to focus on more complex, high-value testing.
The most innovative life sciences companies are working to advance this field by addressing challenges in quality control, data management, and regulatory compliance and finding bold new solutions.
The future of lab-grade accuracy at the point of need
The move toward decentralized testing is reshaping the diagnostic landscape. By bringing rapid, reliable molecular testing closer to the patient, leading organizations are enhancing antimicrobial stewardship, optimizing workflows, and improving patient outcomes. Their continued innovation solidifies their position among the best life sciences companies for research and diagnostics, demonstrating the profound impact of accessible molecular information at the point of care.
